Despite significant success of targeted anticancer therapies in ER + or HER2 + subtypes of breast cancers, patients with loco-regionally advanced or metastatic triple negative carcinoma have very limited therapy options, especially as chemo-resistance develops to standard chemotherapy. Here, ERBB2 is linked to breast carcinoma.